Cargando…

The Clinical Utility of miR-21 and let-7 in Non-small Cell Lung Cancer (NSCLC). A Systematic Review and Meta-Analysis

Non-small cell lung cancer (NSCLC) remains a problem worldwide due to its rapid progression and low rate of response to treatment. The heterogeneity of these tumors observed in histopathology exam but also in the mutational status and gene expression pattern makes this malignancy difficult to treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Pop-Bica, Cecilia, Pintea, Sebastian, Magdo, Lorand, Cojocneanu, Roxana, Gulei, Diana, Ferracin, Manuela, Berindan-Neagoe, Ioana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604406/
https://www.ncbi.nlm.nih.gov/pubmed/33194579
http://dx.doi.org/10.3389/fonc.2020.516850
_version_ 1783604138391633920
author Pop-Bica, Cecilia
Pintea, Sebastian
Magdo, Lorand
Cojocneanu, Roxana
Gulei, Diana
Ferracin, Manuela
Berindan-Neagoe, Ioana
author_facet Pop-Bica, Cecilia
Pintea, Sebastian
Magdo, Lorand
Cojocneanu, Roxana
Gulei, Diana
Ferracin, Manuela
Berindan-Neagoe, Ioana
author_sort Pop-Bica, Cecilia
collection PubMed
description Non-small cell lung cancer (NSCLC) remains a problem worldwide due to its rapid progression and low rate of response to treatment. The heterogeneity of these tumors observed in histopathology exam but also in the mutational status and gene expression pattern makes this malignancy difficult to treat in clinic. The present study investigated the effect of miR-21 and let-7 family members as prognostic biomarkers in NSCLC patients based on the results published in different studies regarding this subject until March 2019. The analysis revealed that these two transcripts are steady biomarkers for prediction of patient outcome or survival. Upregulated expression of miR-21 is associated with poor outcome of patients with NSCLC [HR = 1.87, 95% CI = (1.41, 2.47), p < 0.001]. The analysis regarding let-7 family, specifically let-7a/b/e/f, revealed that downregulated expression of these transcripts predicts poor outcome for NSCLC patients [HR = 2.61, 95% CI = (1.58, 4.30), p < 0.001]. Besides, the reliability of these microRNAs is reflected in the fact that their prognostic significance is constant given the different sample types (tissue, FFPE tissue, serum, serum/plasma or exosomes) used in the selected studies.
format Online
Article
Text
id pubmed-7604406
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-76044062020-11-13 The Clinical Utility of miR-21 and let-7 in Non-small Cell Lung Cancer (NSCLC). A Systematic Review and Meta-Analysis Pop-Bica, Cecilia Pintea, Sebastian Magdo, Lorand Cojocneanu, Roxana Gulei, Diana Ferracin, Manuela Berindan-Neagoe, Ioana Front Oncol Oncology Non-small cell lung cancer (NSCLC) remains a problem worldwide due to its rapid progression and low rate of response to treatment. The heterogeneity of these tumors observed in histopathology exam but also in the mutational status and gene expression pattern makes this malignancy difficult to treat in clinic. The present study investigated the effect of miR-21 and let-7 family members as prognostic biomarkers in NSCLC patients based on the results published in different studies regarding this subject until March 2019. The analysis revealed that these two transcripts are steady biomarkers for prediction of patient outcome or survival. Upregulated expression of miR-21 is associated with poor outcome of patients with NSCLC [HR = 1.87, 95% CI = (1.41, 2.47), p < 0.001]. The analysis regarding let-7 family, specifically let-7a/b/e/f, revealed that downregulated expression of these transcripts predicts poor outcome for NSCLC patients [HR = 2.61, 95% CI = (1.58, 4.30), p < 0.001]. Besides, the reliability of these microRNAs is reflected in the fact that their prognostic significance is constant given the different sample types (tissue, FFPE tissue, serum, serum/plasma or exosomes) used in the selected studies. Frontiers Media S.A. 2020-10-19 /pmc/articles/PMC7604406/ /pubmed/33194579 http://dx.doi.org/10.3389/fonc.2020.516850 Text en Copyright © 2020 Pop-Bica, Pintea, Magdo, Cojocneanu, Gulei, Ferracin and Berindan-Neagoe. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Pop-Bica, Cecilia
Pintea, Sebastian
Magdo, Lorand
Cojocneanu, Roxana
Gulei, Diana
Ferracin, Manuela
Berindan-Neagoe, Ioana
The Clinical Utility of miR-21 and let-7 in Non-small Cell Lung Cancer (NSCLC). A Systematic Review and Meta-Analysis
title The Clinical Utility of miR-21 and let-7 in Non-small Cell Lung Cancer (NSCLC). A Systematic Review and Meta-Analysis
title_full The Clinical Utility of miR-21 and let-7 in Non-small Cell Lung Cancer (NSCLC). A Systematic Review and Meta-Analysis
title_fullStr The Clinical Utility of miR-21 and let-7 in Non-small Cell Lung Cancer (NSCLC). A Systematic Review and Meta-Analysis
title_full_unstemmed The Clinical Utility of miR-21 and let-7 in Non-small Cell Lung Cancer (NSCLC). A Systematic Review and Meta-Analysis
title_short The Clinical Utility of miR-21 and let-7 in Non-small Cell Lung Cancer (NSCLC). A Systematic Review and Meta-Analysis
title_sort clinical utility of mir-21 and let-7 in non-small cell lung cancer (nsclc). a systematic review and meta-analysis
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604406/
https://www.ncbi.nlm.nih.gov/pubmed/33194579
http://dx.doi.org/10.3389/fonc.2020.516850
work_keys_str_mv AT popbicacecilia theclinicalutilityofmir21andlet7innonsmallcelllungcancernsclcasystematicreviewandmetaanalysis
AT pinteasebastian theclinicalutilityofmir21andlet7innonsmallcelllungcancernsclcasystematicreviewandmetaanalysis
AT magdolorand theclinicalutilityofmir21andlet7innonsmallcelllungcancernsclcasystematicreviewandmetaanalysis
AT cojocneanuroxana theclinicalutilityofmir21andlet7innonsmallcelllungcancernsclcasystematicreviewandmetaanalysis
AT guleidiana theclinicalutilityofmir21andlet7innonsmallcelllungcancernsclcasystematicreviewandmetaanalysis
AT ferracinmanuela theclinicalutilityofmir21andlet7innonsmallcelllungcancernsclcasystematicreviewandmetaanalysis
AT berindanneagoeioana theclinicalutilityofmir21andlet7innonsmallcelllungcancernsclcasystematicreviewandmetaanalysis
AT popbicacecilia clinicalutilityofmir21andlet7innonsmallcelllungcancernsclcasystematicreviewandmetaanalysis
AT pinteasebastian clinicalutilityofmir21andlet7innonsmallcelllungcancernsclcasystematicreviewandmetaanalysis
AT magdolorand clinicalutilityofmir21andlet7innonsmallcelllungcancernsclcasystematicreviewandmetaanalysis
AT cojocneanuroxana clinicalutilityofmir21andlet7innonsmallcelllungcancernsclcasystematicreviewandmetaanalysis
AT guleidiana clinicalutilityofmir21andlet7innonsmallcelllungcancernsclcasystematicreviewandmetaanalysis
AT ferracinmanuela clinicalutilityofmir21andlet7innonsmallcelllungcancernsclcasystematicreviewandmetaanalysis
AT berindanneagoeioana clinicalutilityofmir21andlet7innonsmallcelllungcancernsclcasystematicreviewandmetaanalysis